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Abstract
Nasopharyngeal carcinoma (NPC) arises from the epithelial lining of the 
nasopharynx. Stage I-IIa disease can be cured by radiotherapy alone. Locally 
or locoregionally advanced disease (stage III, IVA, and IVB) is treated with 
a combination of radiotherapy with concurrent chemotherapy (CRT). This 
treatment modality provides 5-year overall survival rates of 50–70%.
We present the case of a 28-year old woman; diagnosed with UNPC 
cT4cN2M0, stage IVa. After primary cisplatin-based CRT with curative intent, 
there was a complete locoregional remission. However, within six months after 
completion of primary treatment, bone metastases became apparent. The 
patient was treated repeatedly with radiotherapy at metastatic sites to avoid 
additional chemotherapy (renal insufficiency present). Eventually, the patient 
died at the age of 35, seven years after primary diagnosis.
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Introduction
Nasopharyngeal carcinoma (NPC) arises from the epithelial 
lining of the nasopharynx. It represents 75-95% of the malignancies 
originating from the nasopharynx. The incidence and prevalence 
of NPC is high in South East Asia, while it is lower in Europe. In 
Belgium, approximately 60 new diagnoses are made every year [1].
From pathological point of view, three types of NPC are 
described: keratinising squamous cell carcinoma (Type I), non-
keratinising differentiated carcinoma (Type II) and non-keratinising 
undifferentiated carcinoma (Type III) [2]. Epstein- Barr virus (EBV) 
is postulated to play a key-role in the pathophysiology of type II and 
III NPC. In addition, genetics and environmental factors such as 
tobacco use, alcohol consumption and intake of salt-preserved food 
have been identified as possible risk factors [3].
Diagnosis of NPC is usually based on symptoms related to 
tumor growth into surrounding structures. Endoscopic examination 
is mandatory to confirm diagnosis. Staging is based on physical 
examination combined with imaging studies, i.e. computed 
tomography (CT) scan or magnetic resonance imaging (MRI) [4].
NPC is highly curable in early stage disease. The treatment of 
choice for stage I-IIa NPC is radiotherapy with 5-year overall survival 
rates up to 95%. Therapeutic options available for more advanced 
disease include concurrent chemoradiotherapy (CRT) associated 
with (neo) adjuvant chemotherapy. Metastatic disease is known to be 
chemosensitive, but remains essentially incurable [5].
In case of treatment with curative intent, rigorous patient follow-
up is required, with a primarily clinical focus. Imaging by CT or MRI 
might be useful in follow-up of patients diagnosed with T3 or T4 NPC 
[4].
Case Presentation
In August 2006, a 28-year old woman was admitted to the 
department of Head and Neck Surgery at the Ghent University 
Hospital. A history of sinusitis, tracheitis and an eye correcting 
surgery at the age of three was withheld. The patient did not smoke or 
used alcohol. At the moment of admission she took ibuprofen (400mg 
a day) and paracetamol (1000mg 1 to 4 a day). She was suffering 
from nasal obstruction and intermittent epistaxis since a few weeks. 
Moreover, the patient mentioned a cervical nodular mass on the right 
(region II), diplopia, cervical discomfort and fatigue. She also noticed 
a weight loss of 15 kilogram over the past six months. Except from 
Figure 1: Undifferentiated nasopharyngeal carcinoma. 
Neoplastic cell nests with syncytial growth pattern and interspersed non-
neoplastic lymphoid component. Tumor cells have round to oval nuclei, 
prominent eosinophilic nucleoli and scant cytoplasm. (Hematoxylin and eosin 
stain [HE], magnification x200)
Austin J Otolaryngol 2(1): id1026 (2015)  - Page - 02
Rottey Sylvie Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
the nodular mass, clinical investigation was normal. Endoscopic 
inspection showed a large nasopharyngeal mass. On histological 
examination of the biopsies, diagnosis of undifferentiated NPC 
(UNPC) was made (Figure 1). In-situ-hybridization for EBV-DNA 
was strongly positive (Figure 2). Additionally, a CT scan of the neck 
and the chest and MRI of the brain were performed. No arguments 
for metastatic disease were retained. CT scan did show a large tumor 
mass extending to the sphenoidal sinus/ the pterygopalatine fossa 
with bilateral multifocal pathological lymph nodes. Based on these 
findings, the patient was diagnosed with UNPC cT4cN2M0; stage IVa 
according to the Union for International Cancer Control (UICC). 
During the multidisciplinary team meeting, cisplatinum based CRT 
followed by combination chemotherapy, was proposed as the best 
treatment option for this patient.
Radiotherapy (64Gy in 2 Gy fractions) with concomitant three-
weekly cisplatinum was administrated in a curative setting. The 
patient received three cycles of cisplatinum 100 mg/m² during 
radiotherapy. In the adjuvant setting, only one cycle (instead of the 
planned three) of cisplatinum+5-fluorouracil could be administrated 
due to severe side-effects (grade III nausea and vomiting, grade IV 
dysphagia, grade III erythema in the radiation field, neutropenic fever 
with pseudomonas sepsis and grade III renal insufficiency). Dysphagia 
and vomiting persisted, with requirement of total parenteral nutrition 
(TPN). TPN needed to be continued on a chronic basis. Complete 
clinical remission was obtained.
Within six months after the last administration of chemotherapy, 
the patient noticed some articular discomfort on the level of the 
left knee, irradiating towards the ipsilateral hip. Bone scintigraphy 
highlighted multifocal metastatic lesions in the left femur, the seventh 
rib and the facial skeleton. Pathological evaluation (open biopsy at 
the left femur) confirmed the presence of metastatic bone lesions of 
the NPC. Surgical fixation was applied to stabilize the left hip after 
which radiotherapy was performed on the hip (36Gy throughout 
12 fractions). Given the presence of renal impairment (GFR 49ml/
min/1.73m²) secondary to prior cisplatinum chemotherapy and a 
Karnofsky score of 60% at that time, chemotherapy was not initiated.
Eighteen months later, CT and PET-CT scan revealed 
lymphonodular bulging with invasion of the left psoas muscle for 
which the patient was treated with local radiotherapy (50Gy in 2 Gy 
fractions), resulting in adequate pain management.
Another six months later the patient felt pain of the left shoulder. 
Radiological evaluation could not show metastatic disease so 
physiotherapy and analgesics were recommended. CT scan of chest 
and abdomen at that time revealed progression of the metastatic 
disease with growing lymph nodes in the lower neck. Still, because 
the patient did not experience any discomfort other than the above 
mentioned pain that was controlled with the proposed interventions, 
watchful waiting was preferred. However, the shoulder pain persisted 
and seemed to be caused by lymphonodular enlargement (cervical 
region III) compressing the brachial plexus for which local palliative 
antalgic radiotherapy, (30Gy in 2 Gy fractions) was performed.
The patient’s condition remained stable over a period of two years. 
In April 2013, 71 months after diagnosis of metastatic disease, her 
condition deteriorated significantly. She felt exhausted and showed 
progressive weight loss. CT imaging showed diffuse metastatic disease: 
two hypodense lesions in the right liver, two micronodular lesions in 
the lower lobe of the right lung, multiple pathological lymph nodes 
in the mediastinum and the mesothelium, pleural effusion on both 
sides, pericardial effusion, a limited amount of fluid in the perineum 
and a solitary lesion on the left adrenal gland.
The option of palliative chemotherapy was discussed with the 
patient again. Because of the renal impairment and the poor general 
condition of the patient and according to her own preference, no 
chemotherapy was initiated. Eventually, the patient died at the age of 
35 due to the disease progression.
An overview of the patient’s case is summarized in Table 1.
Discussion
The incidence of NPC is usually two to three times higher in 
male patients [6]. Also, incidence increases with age in most low-risk 
populations [2,7]. Therefore, our patient does not match the typical 
profile one would expect from a patient diagnosed with NPC. EBV 
infection might only partially explain the development of this rare 
type of cancer. Therefore it is assumed underlying genetic mechanisms 
play an important role in the pathophysiology of NPC [7].
The overall European population taken into count, the relative 
survival for NPC is 76% at one year and 50% at five years [8,9]. Age 
has a significant impact on survival. Survival at five years is 72% for 
those patients ranging from 15 to 45 years and 36% in the eldest group 
of patients (65-74 years). Metastatic disease is an important cause of 
death in NPC and is seen more often in patients with NPC than in 
other patients diagnosed with malignancies arising in the head and 
neck region [10,11].
Our patient survived 71 months from the time metastatic disease 
was diagnosed and almost seven years after primary diagnosis. In this 
context, several factors have been identified as predictors for long-
time survival in case of metastasis: initial diagnosis before the age of 
40, absence of local recurrence and complete response to aggressive 
multimodal therapy. Short disease-free survival after initial therapy 
and diffuse metastatic disease on the other hand were inversely 
correlated with long-time survival. Also, performance status should 
Figure 2: In-situ-hybridization for EBV-DNA.
EBV chromogenic in-situ-hybridization reveals the presence of EBV DNA in 
the tumor cells (blue staining). (magnification x200)
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be taken into account [10,12]. Our patient maintained a Karnofsky 
performance status of 60 over a long period of time. We suggest 
that continuous administration of TPN after the first therapeutic 
intervention may have positively influenced patient’s outcome and 
contributed to prolonged survival [13].
Another unusual feature noted in this case was the fact that our 
patient did not receive chemotherapy for recurrent metastatic disease. 
NPC is characterized by its high chemosensitivity [12]. However, 
clinical burden was small at the time metastasis was diagnosed. 
Moreover, the patient suffered from renal insufficiency secondary 
to prior cisplatinum chemotherapy making further application of 
chemotherapy more complicated. Therefore, it was decided not to 
start palliative chemotherapy but the patient was treated repeatedly 
with radiotherapy at metastatic sites to control symptoms. In this 
context it is important to mention that ionizing radiation not only 
offers local benefits but can involve systemic immune activation 
inducing out-of-field antitumor reactions (= “abscopal effect”) 
[14,15]. However difficult to address in this specific case, this abscopal 
effect might have resulted in regression of lesions that are outside the 
radiation field. We can conclude that radiotherapy, together with best 
supportive care, analgesics and TPN, kept quality of life as high as 
possible and may have influenced survival in this patient.
Conclusion
We presented the case of a 28-year old woman with stage IVa 
UNPC, initially treated with curative intent with CRT. Metastatic 
disease was diagnosed only six months after treatment. Although she 
never received systemic treatment for her metastases, she survived 71 
months with only radiotherapy and antalgic medication.
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